Biosimilar Interchangeability: Limited Exclusivity Should Mean Limited Testing – GPhA

Although AbbVie is petitioning FDA for expansive definition of 'any given patient' requirement, GPhA and its Biosimilars Council argue that Congress knew how to write the statute more broadly, but didn't.